A Reversal for Apellis Pharmaceuticals, Inc. (APLS) Is Not Near. The Stock Declines Again

April 17, 2018 - By Stephen Andrade

The stock of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a huge mover today! The stock decreased 16.60% or $4.98 during the last trading session, reaching $25.02. About 591,298 shares traded or 418.92% up from the average. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.
The move comes after 6 months negative chart setup for the $1.26B company. It was reported on Apr, 17 by Barchart.com. We have $23.77 PT which if reached, will make NASDAQ:APLS worth $63.00M less.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.26 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.